 Amyris Inc NASDAQ: AMRS has entered into a 50:50 joint venture arrangement with ImmunityBio Inc NASDAQ: IBRX to commercialize a next-gen COVID-19 vaccine. The parties have signed a binding term sheet, and a definitive agreement is in process and is expected to be executed within the next month. 